Home > Back to Publisher > Report Information

The 2009-2014 World Outlook for In-Vitro Diagnostic Blood Bank, Hematology and Coagulation Products

Icon Group International, Inc.
September 27, 2008
188 Pages - SKU: ICON1955633

Abstract Table of Contents Related Reports

Countries covered: Global

This econometric study covers the world outlook for in-vitro diagnostic blood bank, hematology and coagulation products across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created.

This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the 230 countries of the world). This study gives, however, my estimates for the worldwide latent demand, or the P.I.E., for in-vitro diagnostic blood bank, hematology and coagulation products. It also shows how the P.I.E. is divided across the world’s regional and national markets. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business.

Additional Information

This econometric study covers the world outlook for in-vitro diagnostic blood bank, hematology and coagulation

1 INTRODUCTION: 1.1 Overview; 1.2 What is Latent Demand and the P.I.E.?; 1.3 The Methodology
2 SUMMARY OF FINDINGS: 2.1 The Worldwide Market Potential
3 AFRICA: 3.1 Executive Summary; 3.2 Algeria; 3.3 Angola; 3.4 Benin; 3.5 Botswana; 3.6 Burkina Faso; 3.7 Burundi; 3.8 Cameroon; 3.9 Cape Verde; 3.10 Central African Republic; 3.11 Chad; 3.12 Comoros; 3.13 Congo (formerly Zaire); 3.14 Cote d'Ivoire; 3.15 Djibouti; 3.16 Egypt; 3.17 Equatorial Guinea; 3.18 Ethiopia; 3.19 Gabon; 3.20 Ghana; 3.21 Guinea; 3.22 Guinea-Bissau; 3.23 Kenya; 3.24 Lesotho; 3.25 Liberia; 3.26 Libya; 3.27 Madagascar; 3.28 Malawi; 3.29 Mali; 3.30 Mauritania; 3.31 Mauritius; 3.32 Morocco; 3.33 Mozambique; 3.34 Namibia; 3.35 Niger; 3.36 Nigeria; 3.37 Republic of Congo; 3.38 Reunion; 3.39 Rwanda; 3.40 Sao Tome E Principe; 3.41 Senegal; 3.42 Sierra Leone; 3.43 Somalia; 3.44 South Africa; 3.45 Sudan; 3.46 Swaziland; 3.47 Tanzania; 3.48 The Gambia; 3.49 Togo; 3.50 Tunisia; 3.51 Uganda; 3.52 Western Sahara; 3.53 Zambia; 3.54 Zimbabwe
4 ASIA & OCEANA: 4.1 Executive Summary; 4.2 American Samoa; 4.3 Australia; 4.4 Bangladesh; 4.5 Bhutan; 4.6 Brunei; 4.7 Burma; 4.8 Cambodia; 4.9 China; 4.10 Christmas Island; 4.11 Cook Islands; 4.12 Fiji; 4.13 French Polynesia; 4.14 Guam; 4.15 Hong Kong; 4.16 India; 4.17 Indonesia; 4.18 Japan; 4.19 Kiribati; 4.20 Laos; 4.21 Macau; 4.22 Malaysia; 4.23 Maldives; 4.24 Marshall Islands; 4.25 Micronesia Federation; 4.26 Mongolia; 4.27 Nauru; 4.28 Nepal; 4.29 New Caledonia; 4.30 New Zealand; 4.31 Niue; 4.32 Norfolk Island; 4.33 North Korea; 4.34 Palau; 4.35 Papua New Guinea; 4.36 Philippines; 4.37 Seychelles; 4.38 Singapore; 4.39 Solomon Islands; 4.40 South Korea; 4.41 Sri Lanka; 4.42 Taiwan; 4.43 Thailand; 4.44 The Northern Mariana Island; 4.45 Tokelau; 4.46 Tonga; 4.47 Tuvalu; 4.48 Vanuatu; 4.49 Vietnam; 4.50 Wallis and Futuna; 4.51 Western Samoa
5 EUROPE: 5.1 Executive Summary; 5.2 Albania; 5.3 Andorra; 5.4 Austria; 5.5 Belarus; 5.6 Belgium; 5.7 Bosnia and Herzegovina; 5.8 Bulgaria; 5.9 Croatia; 5.10 Cyprus; 5.11 Czech Republic; 5.12 Denmark; 5.13 Estonia; 5.14 Finland; 5.15 France; 5.16 Georgia; 5.17 Germany; 5.18 Greece; 5.19 Hungary; 5.20 Iceland; 5.21 Ireland; 5.22 Italy; 5.23 Kazakhstan; 5.24 Latvia; 5.25 Liechtenstein; 5.26 Lithuania; 5.27 Luxembourg; 5.28 Malta; 5.29 Moldova; 5.30 Monaco; 5.31 Norway; 5.32 Poland; 5.33 Portugal; 5.34 Romania; 5.35 Russia; 5.36 San Marino; 5.37 Slovakia; 5.38 Slovenia; 5.39 Spain; 5.40 Sweden; 5.41 Switzerland; 5.42 The Netherlands; 5.43 The United Kingdom; 5.44 Ukraine
6 LATIN AMERICA: 6.1 Executive Summary; 6.2 Argentina; 6.3 Belize; 6.4 Bolivia; 6.5 Brazil; 6.6 Chile; 6.7 Colombia; 6.8 Costa Rica; 6.9 Ecuador; 6.10 El Salvador; 6.11 French Guiana; 6.12 Guatemala; 6.13 Guyana; 6.14 Honduras; 6.15 Mexico; 6.16 Nicaragua; 6.17 Panama; 6.18 Paraguay; 6.19 Peru; 6.20 Suriname; 6.21 The Falkland Islands; 6.22 Uruguay; 6.23 Venezuela
7 NORTH AMERICA & THE CARIBBEAN: 7.1 Executive Summary; 7.2 Antigua and Barbuda; 7.3 Aruba; 7.4 Barbados; 7.5 Bermuda; 7.6 Canada; 7.7 Cuba; 7.8 Dominica; 7.9 Dominican Republic; 7.10 Greenland; 7.11 Grenada; 7.12 Guadeloupe; 7.13 Haiti; 7.14 Jamaica; 7.15 Martinique; 7.16 Puerto Rico; 7.17 St. Kitts and Nevis; 7.18 St. Lucia; 7.19 St. Vincent and the Grenadines; 7.20 The Bahamas; 7.21 The British Virgin Islands; 7.22 The Cayman Islands; 7.23 The Netherlands Antilles; 7.24 The U.S. Virgin Islands; 7.25 The United States; 7.26 Trinidad and Tobago
8 THE MIDDLE EAST: 8.1 Executive Summary; 8.2 Afghanistan; 8.3 Armenia; 8.4 Azerbaijan; 8.5 Bahrain; 8.6 Iran; 8.7 Iraq; 8.8 Israel; 8.9 Jordan; 8.10 Kuwait; 8.11 Kyrgyzstan; 8.12 Lebanon; 8.13 Oman; 8.14 Pakistan; 8.15 Palestine; 8.16 Qatar; 8.17 Saudi Arabia; 8.18 Syrian Arab Republic; 8.19 Tajikistan; 8.20 The United Arab Emirates; 8.21 Turkey; 8.22 Turkmenistan; 8.23 Uzbekistan; 8.24 Yemen
9 DISCLAIMERS, WARRANTEES, AND USER AGREEMENT PROVISIONS: 9.1 Disclaimers & Safe Harbor; 9.2 ICON Group International, Inc. User Agreement Provisions

More Global Coagulation Reports

2012 Global Hemostasis Diagnostics Market Outlook: Growth Opportunities and Strategies by Venture Planning Group
This comprehensive seven-country report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the hemostasis diagnostics market ...

2012 World Hospital and Point-of-Care Coagulation Testing Market Outlook: Facilities, Test Volumes, Sales Forecasts, and Key Player Market Shares by Venture Planning Group
This report provides a worldwide overview of the coagulation testing market, including estimates of facilities performing coagulation tests, as well as test volume and sales ...

2012 Global PT Testing Market Outlook: Test Volume Forecasts by Country and Market Segment by Venture Planning Group
The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next ten years. New ...

2012 Global Proteins C and S Market Outlook: Test Volume Forecasts by Country and Market Segment by Venture Planning Group
The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next ten years. New ...

2012 Global Heparin Market Outlook: Test Volume Forecasts by Country and Market Segment by Venture Planning Group
The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next ten years. New ...

See all reports like this >>

The 2009-2014 World Outlook for In-Vitro Diagnostic Blood Bank, Hematology and Coagulation Products

Share this report

Other tasks

Research Assistance

Related Markets

Coagulation Reports

Free Alert Me service